Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

There is a lack of effective solution in standard fertility benefit packages and PGNY is addressing this gap. PGNY's approach drives down the overall cost.

Progyny: Expect Fast Growth Despite A Weak Macro Backdrop

Five Below

Hologic

Impinj

Yum China Hlds

These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).

In Search of an Earnings Beat? Play These Top 5 Stocks

Advanced Micro Devices

Amazon

Alibaba

Enphase Energy

NVIDIA

PayPal

With a rough 2022 spilling into 2023, we're running into a broad list of stocks to avoid. Especially those in the tech space, where high-profile layoffs have picked up amid a severe slowdown in growth.

7 Stocks With a Forward P/E of 25 to Run Away From

Anticipates Results to be at the High-End of its Previously Provided Financial GuidanceAnticipates Reporting Record Fourth Quarter Operating Cash Flow of Approximately $50 Million

Progyny to Discuss its Strong 2022 Financial Performance at Upcoming Investor Conference

Kinsale Capital Group

Lovesac Company

SoFi Technologies

Three-year revenue growth rates between 39% and 54% are projected, making these stocks prime multibagger candidates.

4 Unstoppable Multibaggers to Buy in 2023 and Hold for the Next Decade

Compared to many newly listed public companies in recent years, Progyny is thriving as client count and revenues have grown tremendously. Progyny is the market leader in the fertility benefits arena, with a proven and successful management team.

Progyny: A Winner For Years To Come

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ: PGNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Progyny and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Progyny, Inc. - PGNY

Elevance Health Inc

ELV vs. PGNY: Which Stock Is the Better Value Option?

Chegg

Chewy

Fortinet

KnowBe4

These top-ranked stocks -- Chewy (CHWY), Progyny (PGNY), KnowBe4 (KNBE), Chegg (CHGG) and Fortinet (FTNT) -- are likely to beat on their bottom line in the next releases.

Looking for Earnings Beat? Buy These 5 Stocks With Potential

NEW YORK , Dec. 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Progyny securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PGNY EQUITY NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation - PGNY

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Progyny, Inc. (“Progyny” or “the Company”) (NASDAQ: PGNY) for violations of the securities laws.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Progyny, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - December 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ: PGNY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Progyny, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - December 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ: PGNY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Progyny, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progyny, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Progyny, Inc. (NASDAQ: PGNY) resulting from allegations that Progyny may have issued materially misleading business information to the investing public.

PGNY INVESTOR NOTICE: Rosen Law Firm Encourages Progyny, Inc. Investors to Inquire About Securities Class Action Investigation – PGNY

ELV vs. PGNY: Which Stock Should Value Investors Buy Now?

Progyny Inc (NASDAQ:PGNY) announced that shipments of its fertility medication Menopur have resumed following an industry wide shortage, prompting the company to boost its fourth quarter and full year guidance. During the company's earnings call on November 3, executives said that the assumption was that Menopur would not be available for the remainder of 2022.

Progyny stock grows after fertility drug shipments resume, upping 4Q guidance

Shares of Progyny Inc. PGNY, +0.17% gained 0.4% in premarket trading Monday, after the fertility benefits management company raised is fourth-quarter financial outlook, given the surprising resumption of deliveries fertility drug Menopur. The company raised its guidance ranges for fourth-quarter earnings per share to 2 cents to 3 cents from a per-share loss of 1 cents to EPS of 2 cents, and for revenue to $208.9 million to $213.9 million from $202.4 million to $212.4 million.

Fertility manager Progyny stock gains as resumption of Menopur deliveries leads to raised guidance

Shipments of Key Fertility Medication Have Resumed Shipments of Key Fertility Medication Have Resumed

Progyny Raises 2022 Financial Guidance

ELV or PGNY: Which Is the Better Value Stock Right Now?

The consensus price target hints at a 63.5% upside potential for Progyny (PGNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 64% Upside in Progyny (PGNY): Can the Stock Really Move This High?

NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022 at 4:25 P.M. Pacific Time, or 7:25 P.M. Eastern Time.

Progyny, Inc. to Present at Credit Suisse 31st Annual Healthcare Conference

Progyny, Inc. (NASDAQ:PGNY ) Q3 2022 Earnings Conference Call November 3, 2022 4:45 PM ET Company Participants James Hart - VP, IR Peter Anevski - CEO Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Glen Santangelo - Jefferies Sarah James - Barclays Stephanie Davis - SVB Securities Deb Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny, Inc. Third Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

Progyny, Inc. (PGNY) CEO Peter Anevski on Q3 2022 Results - Earnings Call Transcript

Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Q3 Earnings and Revenues Top Estimates

Receives Record Number of New Client Commitments in Selling SeasonReports Record Quarterly Revenue of $205.4 Million, Reflecting 68% Growth Over the Prior Year PeriodRaises Full Year 2022 Guidance, Reflecting Fourth Quarter Revenue Growth of 59% to 67%

News for Progyny Stock (PGNY)